← Back to Search

Corticosteroid

Miricorlilant for Weight Gain

Phase 2
Waitlist Available
Research Sponsored by Corcept Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline day 1 to week 26
Awards & highlights

Study Summary

This trial is testing a new drug, called miricorilant, to see if it is safe and effective in treating obese patients with schizophrenia who are also taking antipsychotic medication.

Eligible Conditions
  • Weight Gain

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline day 1 to week 26
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline day 1 to week 26 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline in body weight
Secondary outcome measures
Change from baseline in body weight for both dose levels of miricorilant combined versus placebo
Change from baseline in waist-to-hip ratio for miricorilant versus placebo
Percentage of patients achieving a ≥5% weight loss for miricorilant versus placebo

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Miricorlilant - 900 mgExperimental Treatment1 Intervention
Patients who meet the entry criteria for the Study CORT118335-877 will be randomized to receive 900 mg miricorilant once daily for 26 weeks.
Group II: Miricorlilant - 600 mgExperimental Treatment1 Intervention
Patients who meet the entry criteria for the Study CORT118335-877 will be randomized to receive 600 mg miricorilant once daily for 26 weeks.
Group III: PlaceboPlacebo Group1 Intervention
Patients who meet the entry criteria for the Study CORT118335-877 will be randomized to receive placebo once daily for 26 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Miricorlilant
2020
Completed Phase 2
~160

Find a Location

Who is running the clinical trial?

Corcept TherapeuticsLead Sponsor
68 Previous Clinical Trials
6,229 Total Patients Enrolled
5 Trials studying Weight Gain
326 Patients Enrolled for Weight Gain
Kavita Juneja, MDStudy DirectorCorcept Therapeutics
4 Previous Clinical Trials
313 Total Patients Enrolled
1 Trials studying Weight Gain
71 Patients Enrolled for Weight Gain
Ada Lee, MDStudy DirectorCorcept Therapeutics
5 Previous Clinical Trials
194 Total Patients Enrolled
1 Trials studying Weight Gain
71 Patients Enrolled for Weight Gain

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)
2020. "Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04524403.
~33 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top